A Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension versus Standard Pump Therapy for Hypoglycemic Unaware Patients with Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the cost-effectiveness of sensor-augmented insulin pump therapy with "Low Glucose Suspend" (LGS) functionality versus standard pump therapy with self-monitoring of blood glucose in patients with type 1 diabetes who have impaired awareness of hypoglycemia. METHODS: A clinical trial-based economic evaluation was performed in which the net costs and effectiveness of the two treatment modalities were calculated and expressed as an incremental cost-effectiveness ratio (ICER). The clinical outcome of interest for the evaluation was the rate of severe hypoglycemia in each arm of the LGS study. Quality-of-life utility scores were calculated using the three-level EuroQol five-dimensional questionnaire. Resource use costs were estimated using public sources. RESULTS: After 6 months, the use of sensor-augmented insulin pump therapy with LGS significantly reduced the incidence of severe hypoglycemia compared with standard pump therapy (incident rate difference 1.85 [0.17-3.53]; P = 0.037). Based on a primary randomized study, the ICER per severe hypoglycemic event avoided was $18,257 for all patients and $14,944 for those aged 12 years and older. Including all major medical resource costs (e.g., hospital admissions), the ICERs were $17,602 and $14,289, respectively. Over the 6-month period, the cost per quality-adjusted life-year gained was $40,803 for patients aged 12 years and older. CONCLUSIONS: Based on the Australian experience evaluating new interventions across a broad range of therapeutic areas, sensor-augmented insulin pump therapy with LGS may be considered a cost-effective alternative to standard pump therapy with self-monitoring of blood glucose in hypoglycemia unaware patients with type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Frequency of Severe Hypoglycemia Requiring Emergency Treatment in Type 1 and Type 2 Diabetes
Leese, G. P., Wang, J., Broomhall, J., Kelly, P., Marsden, A., Morrison, W., Frier, B. M., Morris, A. D., & For the DARTS/MEMO Collaboration (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1176 · Cited by 559 · cited 2×
“[34] Leese GP, Wang J, Broomhall J, et al.”
BackgroundLy, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411 · cited 15×
“Participants were randomized to receive sensor-augmented insulin pump therapy with automated insulin suspension (LGS pump, n ¼ 46) or standard pump therapy and SMBG (standard pump, n ¼ 49) and were followed for a period of 6 months.”
BackgroundMethodInfluentialSelf-citationInsulin-pump therapy for type 1 diabetes mellitus
Pickup, J. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1113948 · Cited by 270
Fear of hypoglycaemia in parents of young children with type 1 diabetes: A systematic review
Barnard, K., Thomas, S., Royle, P., Noyes, K., & Waugh, N. (2010) · BMC Pediatrics · doi:10.1186/1471-2431-10-50 · Cited by 239 · cited 3×
“Given the effect of hypoglycemia on health-related quality of life in patients with type 1 diabetes [10,25], we calculated quality-oflife utility scores associated with each treatment based on the EQ-5D-3L questionnaire instrument.”
BackgroundMethodLy, T. T., Hewitt, J., Davey, R. J., Lim, E. M., Davis, E. A., & Jones, T. W. (2011) · Diabetes Care · doi:10.2337/dc10-1042 · Cited by 81 · cited 1×
“The use of RT-CGM with an insulin pump that features automated insulin suspension, that is, Low Glucose Suspend (LGS) pump, can further assist in avoiding hypoglycemia and improving epinephrine responses to hypoglycemia in patients with reduced hypoglycemic awareness [15].”
MethodSelf-citation
Cited by
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
“• While the interpretation of average blood glucose is relatively straightforward, providing a direct relationship to HbA1c, GV is a reflection of a dynamic process, and its understanding and measuring are less apparent (69, 70) [E,C].”
BackgroundSelf-citationGrunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Fonseca, V. A., Grunberger, G., Anhalt, H., Bailey, T. S., Blevins, T., Garg, S. K., Handelsman, Y., Hirsch, I. B., Orzeck, E. A., Roberts, V. L., et al. (2016) · Endocrine Practice · doi:10.4158/ep161392.cs · Cited by 195
“(ICER) of AUS $18,257 per severe hypoglycemic event avoided (50).”
BackgroundPease, A., Zomer, E., Liew, D., Earnest, A., Soldatos, G., Ademi, Z., & Zoungas, S. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0064 · Cited by 39
Hirsch, I. B., & Verderese, C. A. (2017) · Endocrine Practice · doi:10.4158/ep171962.ra · Cited by 22
Metadata
- Authors
- Ly, T. T., Brnabic, A. J. M., Eggleston, A., Kolivos, A., McBride, M. E., Schrover, R., & Jones, T. W.
- Venue
- Value in Health
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 17
- Issue
- 5
- Pages
- 561-569
- ISSN
- 1098-3015 (ISSN-L)
- OpenAlex
- W2019222653
- Cited by
- 43
- References
- 7
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.